Objective: To evaluate plasma 8-hydroxy-deoxy-guanosine (8OHdG) levels as a potential biomarker of premanifest and early Huntington disease (HD).Methods: Personnel from 2 independent laboratories quantified 8OHdG in blinded longitudinal plasma samples taken 24 months apart from 160 TRACK-HD participants, as well as samples containing control plasma with added ("spiked") 8OHdG. One laboratory used a liquid chromatography-electrochemical array (LCECA) assay, and the other used liquid chromatography-mass spectrometry (LCMS).Results: The LCMS assay was more accurate than the LCECA assay for measurements of "spiked" 8OHdG levels in plasma. Neither assay demonstrated cross-sectional differences in plasma 8OHdG among controls, premanifest HD, and early symptomatic HD. Similarly, neither assay showed longitudinal changes in any disease group over 24 months.Conclusions: Plasma concentration of 8OHdG is not a biomarker of disease state or progression in HD. We recommend that future putative biomarker studies use blinded sample analysis, standard curves, independent analytical methods, and strict quality control of sample collection and storage. Huntington disease (HD), an autosomal dominant neurodegenerative disease, is caused by an abnormally expanded trinucleotide (CAG) repeat in the huntingtin (HTT) gene. 1 The disorder is typically diagnosed at onset of motor symptoms, but there is a "premanifest" period associated with clinical signs, including brain atrophy, psychiatric symptoms, and cognitive decline. [2][3][4] PREDICT-HD 5 and TRACK-HD, 6 both longitudinal observational studies, aim to identify early HD biomarkers. These and other studies have shown differences in neuroimaging, cognitive, and motor measures among control, premanifest, and clinically diagnosed cohorts. 7,8 Although premanifest and clinically diagnosed groups show robust longitudinal changes in neuroimaging measures, the latter shows more easily detectable declines in other measures compared with controls and premanifest HD (preHD).
9-14Currently, there are no validated candidate blood, CSF, or urine biomarkers that track the progression of HD.15 8-Hydroxy-deoxy-guanosine (8OHdG) has been proposed as a biomarker of HD progression.16 8OHdG is a product of the oxidation of guanine by reactive oxygen species, and its levels in blood and urine may correlate with the degree of oxidative DNA damage. 17,18 Although increased levels of 8OHdG have been reported in patients with HD and mouse models indicating such oxidative DNA damage, the role of such damage in HD pathogenesis remains obscure. [19][20][21][22][23] Using our recently developed liquid chromatography-mass spectrometry (LCMS) assay, we were unable to replicate the modest increase previously demonstrated with the liquid chromatographyFrom CHDI Management/CHDI Foundation (B.B., J.W., C.S.),